ASH News Daily 2012 - Sunday, December 9, 2012 - (Page B-10)

Page B–10 ® ASH NewS DAily The conduct of good clinical research has become a highly specialized and complex endeavor. While appropriate training in rigorous and innovative trial design is essential, the investigator must also be knowledgeable about regulatory, budgetary, and ethical issues. The clinical research enterprise is more dependent than ever on multiple team members including investigators, clinical research coordinators, research nurses, informatics specialists, and biostatisticians. This talk will provide an overview of essential elements needed to build a viable clinical research program. Monday, December 10 12:15 to 1:15 p.m. Building a Successful Research Lab Todd A. Fehniger, MD, PhD, Washington University School of Medicine, St. Louis, MO Running a successful laboratory-based research program goes beyond good science and grant funding. Managing people, money, collaborations, and space are also required skills. This talk will recount lessons learned, including mistakes to be avoided, on the road to becoming an independent laboratory based investigator. Sunday, December 9, 2012 Finding a Good Mentor/ Being a Good Mentee Michael R. DeBaun, MD, Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, TN One of the most important early career choices is finding a mentor. As with any good relationship, expectations need to be aligned and evolve as the mentee develops and the asymmetric interaction becomes more equal. Though mentors are traditionally thought of as a single person, many institutions encourage or even require mentoring teams for all junior faculty, which might consist of several research mentors or an overall career mentor. FocuS on TraineeS Trainee Events «« From Page B-6 Sunday, December 9 11:15 a.m. to 12:15 p.m. Successful Manuscript Writing: How to Get Published in a Peer-Reviewed Journal Cynthia E. Dunbar, MD, Editorin-Chief, Blood, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD Bob Löwenberg, MD, PhD, Editor-in-Chief Designee, Blood, Erasmus University Medical Center, Rotterdam, Netherlands The ability to communicate one’s work effectively by publication in high-impact journals is a benchmark for success in academic medicine. Even high-quality work may not be accepted if not presented in a wellcrafted manuscript. This talk will provide insight into the elements of a high-quality manuscript worthy of publication in Blood, and tips on avoiding common errors that might result in rejection. Building a Successful Clinical Research Program Jennifer R. Brown, MD, PhD, DanaFarber Cancer Institute, Boston, MA CD30-directed therapy Important Safety Information Progressive multifocal leukoencephalopathy (PML): JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS™ (brentuximab vedotin). Concomitant use of ADCETRIS and bleomycin is contraindicated due to pulmonary toxicity. BOXED WARNING CT SCANS confirmed responses in relapsed patients Contraindication: Mx8000 Ex: CT080100137 Se: 8002/4 Im: 130/208 Ax: 1623.9 120.0 kV 280.0 mA 1.3 mm/-0.5:1 Tilt: 0.0 0.0s Lin:DCM/Lin:DCM/id:ID W:200 L25 Warnings and Precautions: Get the latest annual meeting information. Follow us on Twitter @ASH_hematology, and use #ASH12 when tweeting about the meeting. ASH is now on Facebook – connect with us today! http://www. facebook.com/ AmericanSocietyof Hematology • Peripheral neuropathy: ADCETRIS treatment causes a peripheral neuropathy that is predominantly sensory. Cases of peripheral motor neuropathy have also been reported. ADCETRIS-induced peripheral neuropathy is cumulative. Treating physicians should monitor patients for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain or weakness and institute dose modifications accordingly. • Infusion reactions: Infusion-related reactions, including anaphylaxis, have occurred with ADCETRIS. Monitor patients during infusion. If an infusion reaction occurs, the infusion should be interrupted and appropriate medical management instituted. If anaphylaxis occurs, the infusion should be immediately and permanently discontinued and appropriate medical management instituted. • Neutropenia: Monitor complete blood counts prior to each dose of ADCETRIS and consider more frequent monitoring for patients with Grade 3 or 4 neutropenia. If Grade 3 or 4 neutropenia develops, manage by dose delays, reductions or discontinuation. Prolonged (≥1 week) severe neutropenia can occur with ADCETRIS. • Tumor lysis syndrome: Patients with rapidly proliferating tumor and high tumor burden are at risk of tumor lysis syndrome and these patients should be monitored closely and appropriate measures taken. R L 2860_sgn35_fa1_jog_ashnd.indd 1 10/15/12 5:28 PM http://www.facebook.com/AmericanSocietyofHematology http://www.facebook.com/AmericanSocietyofHematology http://www.facebook.com/AmericanSocietyofHematology http://www.facebook.com/AmericanSocietyofHematology http://www.facebook.com/AmericanSocietyofHematology

Table of Contents for the Digital Edition of ASH News Daily 2012 - Sunday, December 9, 2012

ASH News Daily 2012 - Sunday, December 9, 2012

https://www.nxtbookmedia.com